Mind Medicine (MindMed) Inc. reported earnings results for the first quarter ended March 31, 2023. For the first quarter, the company reported net loss was USD 24.82 million compared to USD 18.45 million a year ago. Basic loss per share from continuing operations was USD 0.65 compared to USD 0.66 a year ago.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
7.98 USD | -5.00% | -7.40% | +118.85% |
13/05 | Oppenheimer Adjusts Mind Medicine Price Target to $20 From $29, Maintains Outperform Rating | MT |
08/05 | Transcript : Mind Medicine Inc., Q1 2024 Earnings Call, May 08, 2024 |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+118.85% | 604M | |
+63.86% | 62.59B | |
-1.81% | 41.18B | |
+44.76% | 40.29B | |
-8.93% | 27.9B | |
+12.64% | 26.21B | |
-21.91% | 19.09B | |
+4.25% | 13.08B | |
+25.45% | 12.26B | |
+28.37% | 12.05B |
- Stock Market
- Equities
- MNMD Stock
- News Mind Medicine (MindMed) Inc.
- Mind Medicine Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023